Shots:

• CELLINK expand the collaboration for 12 months and will provide bioprinters and bioinks for acceleration of the exploration of novel targets in AstraZeneca’s 5 main therapy areas: oncology- respiratory- and cardiovascular- renal and metabolic diseases
• The focus of the collaboration is to utilize CELLINK’s portfolio for the creation of seamless workflow from pre-bioprinting preparation of cells to post-bioprinting analysis and will also provide its expertise to work with AZ’s team at their Gaithersburg- US- R&D strategic center
• AstraZeneca will provide its pharmaceutical development expertise for supporting CELLINK to further refine its offerings in industry. In 2018- CELLINK collaborated with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discover

Click here to read full press release/ article

Ref: Newscision | Image: AstraZeneca